drugset / Trial / NCT03159884

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT03159884

Phase 4 Unknown 300 enrolled Chengdu Kanghong Biotech Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.

Timeline

Start
2015-10
Primary completion
2018-06
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Conbercept Protein / enzyme biologic 0.5 mg Intravitreal